CSL (ASX:CSL) share price wobbles on plasma and vaccine update

The CSL Limited (ASX: CSL) share price has been in the spotlight in recent memory. We take a closer look as to what's lowering its shares.

| More on:
A man climbing stairs that go up and down in a chart style, indicating a moving share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been in the spotlight in recent memory. This follows concerns over its plasma collections as well as its progress in producing the AstraZeneca COVID-19 vaccine.

At the time of writing, the global biotech's shares are trading for $264.64, down 1.3% for the day.

Plasma worries

COVID-19 has wreaked havoc on the global economy and virtually shut down foot traffic movement in the United States.

Unfortunately for CSL, this has affected its plasma collections as fewer people are donating blood to its collection centres. The company last provided an update in March advising that December 2020 plasma volumes were sitting around 80% of the December 2019 levels.

This has led CSL to approach the public for ideas on how it can maximise the yield and processing efficiency in human immunoglobulins.

CSL Behring's immunoglobulins are much needed for running its business operations. Derived from plasma, human immunoglobulins are a lifesaving therapy that prevent and fight rare and serious infections.

The company is offering $40,000 on the winning idea as well as two one-on-one mentoring sessions with CSL Behring.

COVID-19 vaccine update

Furthermore, CSL is striving to increase production of the AstraZeneca COVID-19 vaccine. So far, Australia has administered over 1.65 million vaccinations to the public, averaging around 60 thousand doses per day.

The Australian government has indicated that it's strongly considering bringing vaccine manufacturing capability to Australia within the next decade. This would protect Australians from present and future pandemics through local supply, avoiding political problems such as the European shipment block.

CSL has put its hand up for this proposal and is in current discussions with the Australian government. Although, it may take some time to set up such a facility and begin producing important vaccines.

Broker update

The latest broker update came from investment bank Macquarie yesterday, issuing a price target of $282.50 for CSL. While it may have cut its outlook by 1.9% from its original note, this represents an upside of almost 7%.

CSL share price review

Over the last 12 months, the CSL share price has faltered and is now trading at the same price as recorded in November 2019. The company's shares momentarily reached a high of $320.42 in late November 2020 before trending downwards and moving sideways since.

As one of the ASX market's largest companies in terms of market capitalisation, the CSL share price is valued at $120.2 billion. Furthermore, the company has more than 455 million shares on issue.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Happy man working on his laptop.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Two funeral workers with a laptop surrounded by cofins.
Broker Notes

Macquarie just forecast this ASX 300 dividend share could surge 37%. Here's why

Atop its passive income payouts, Macquarie expects this ASX dividend stock could leap 37% in a year.

Read more »

A person in a gorilla suit leaps really high holding a banana, nearly doing the splits.
Share Gainers

Up 1,238% in a year, why is this ASX gold stock surging again on Monday?

The ASX gold stock is now well into ten-bagger range and still rising fast today.

Read more »

A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
Share Gainers

Why EOS, Gorilla Gold, Lendlease, and OFX shares are charging higher today

These shares are starting the week on a positive note. But why?

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Fallers

Why Appen, DroneShield, Gentrack, and New Hope shares are dropping today

These shares are starting the week in the red. But why?

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Materials Shares

Does Macquarie rate James Hardie shares a buy, hold or sell?

The company is set to report FY25 earnings this week.

Read more »

A man looking at his laptop and thinking.
Industrials Shares

Which ASX 200 industrials stock does Macquarie expect to sink 40% over the next 12 months?

Can this name build it's way out of such negative sentiment?

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Share Market News

Will ASX 200 investors get the RBA interest rate cut they're expecting tomorrow?

The RBA is widely expected to cut interest rates on Tuesday. Will the central bank deliver?

Read more »